Atara Biotherapeutics (ATRA) EBIT (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported EBIT for 14 consecutive years, with -$4.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 247.64% year-over-year to -$4.7 million; the trailing twelve-month figure through Jun 2026 stood at -$14.2 million (down 276.96% YoY), and the FY2025 full-year result was $35.9 million, up 142.98% from the prior year.
• EBIT declined to -$4.7 million in Q2 2026 per ATRA's latest filing, from -$3.4 million in the prior quarter.
• Across five years, EBIT topped out at $38.8 million in Q1 2025 and bottomed at -$88.2 million in Q1 2022.
• Historically, EBIT has averaged -$34.0 million across 5 years, with a median of -$26.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: EBIT soared 224.18% in 2025, then sank 247.64% in 2026.
• Over 5 years, EBIT stood at -$75.5 million in 2022, then increased by 20.62% to -$60.0 million in 2023, then surged by 79.65% to -$12.2 million in 2024, then soared by 79.0% to -$2.6 million in 2025, then slumped by 84.16% to -$4.7 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$4.7 million, -$3.4 million, and -$2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.